Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...

In a relatively short time, RFK Jr. has forced America to begin to recognize that the food choices they make have significant ...